Published on March 15, 2005 at 1:23 PM
The Company also announced that the ongoing expansion and upgrading of its Quebec-based flu vaccine manufacturing facilities is on schedule. ID Biomedical expects that with U.S. regulatory approval of Fluviral and a successful pre-approval inspection of its facilities, the company will be able to produce approximately 20 million doses of influenza vaccine for the U.S. market in 2006, and approximately 40 million doses in 2007. ID Biomedical is also committed to develop a preservative-free formulation of its product for the pediatric population.
ID Biomedical produces Fluviral from its two flu vaccine production facilities located in Laval and Quebec City, Quebec. The Company's Quebec City facility is being expanded to increase total manufacturing capacity to approximately 50 million doses by 2007, and will house what is believed to be the newest egg-based vaccine production facility in the world. Upon FDA approval, Fluviral will be distributed in the U.S. by ID Biomedical's distribution partners: Henry Schein, Inc., AmerisourceBergen Corporation's Specialty Group and McKesson Corporation. These distribution partners have agreed to purchase and distribute 38 million doses of the Company's flu vaccine annually beginning in 2007. If ID Biomedical obtains FDA approval by April 1, 2006 under the accelerated approval mechanism, then the agreement will be applicable to the 2006 season as well.
http://www.idbiomed.com/